LXEO Berita Valas

Lexeo Therapeutics Says FDA Grants Fast Track And Orphan Drug Designation To LX2020

Genetic medicine company Lexeo Therapeutics, Inc. (LXEO) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation and Orphan Drug designation to LX2020.

RTTNews | 597 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.16267	GBPUSD	1.33178	AUDUSD	0.64927
USDJPY	147.388	USDCAD	1.37546	USDCHF	0.80677

Advertisement

LXEO Berita Valas

Lexeo Therapeutics Says FDA Grants Fast Track And Orphan Drug Designation To LX2020